CN119013026A - 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法 - Google Patents

用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法 Download PDF

Info

Publication number
CN119013026A
CN119013026A CN202380032303.9A CN202380032303A CN119013026A CN 119013026 A CN119013026 A CN 119013026A CN 202380032303 A CN202380032303 A CN 202380032303A CN 119013026 A CN119013026 A CN 119013026A
Authority
CN
China
Prior art keywords
gdc
administered
pharmaceutically acceptable
acceptable salt
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032303.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·莫钦特
J·L·舒茨曼
时珍
宋春艳
N·V·德里亚
S·R·乔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN119013026A publication Critical patent/CN119013026A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380032303.9A 2022-04-06 2023-04-04 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法 Pending CN119013026A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328149P 2022-04-06 2022-04-06
US63/328,149 2022-04-06
PCT/US2023/017455 WO2023196329A1 (en) 2022-04-06 2023-04-04 Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN119013026A true CN119013026A (zh) 2024-11-22

Family

ID=86286527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032303.9A Pending CN119013026A (zh) 2022-04-06 2023-04-04 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法

Country Status (13)

Country Link
US (2) US12383557B2 (cg-RX-API-DMAC10.html)
EP (1) EP4504202B1 (cg-RX-API-DMAC10.html)
JP (1) JP2025511352A (cg-RX-API-DMAC10.html)
KR (1) KR20240167654A (cg-RX-API-DMAC10.html)
CN (1) CN119013026A (cg-RX-API-DMAC10.html)
AU (1) AU2023249068A1 (cg-RX-API-DMAC10.html)
CA (1) CA3255718A1 (cg-RX-API-DMAC10.html)
ES (1) ES3067080T3 (cg-RX-API-DMAC10.html)
IL (1) IL315250A (cg-RX-API-DMAC10.html)
MX (1) MX2024012230A (cg-RX-API-DMAC10.html)
PL (1) PL4504202T3 (cg-RX-API-DMAC10.html)
TW (1) TW202345846A (cg-RX-API-DMAC10.html)
WO (1) WO2023196329A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250000802A1 (en) * 2023-06-09 2025-01-02 Hoffmann-La Roche Inc. Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
TWI829003B (zh) 2020-08-12 2024-01-11 美商建南德克公司 喹唑啉化合物之合成
EP4243827A1 (en) 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR102975432B1 (ko) 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
TWI895563B (zh) 2020-12-08 2025-09-01 美商建南德克公司 用於治療實性瘤之包含ｋｒａｓｇ１２ｃ抑制劑及ｅｇｆｒ抑制劑之組成物及方法
AR128449A1 (es) 2022-02-07 2024-05-08 Genentech Inc Proceso para la síntesis de compuestos de quinazolina
CN118742544A (zh) 2022-02-07 2024-10-01 基因泰克公司 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式

Also Published As

Publication number Publication date
US12383557B2 (en) 2025-08-12
EP4504202A1 (en) 2025-02-12
US20230321102A1 (en) 2023-10-12
IL315250A (en) 2024-10-01
KR20240167654A (ko) 2024-11-27
AU2023249068A1 (en) 2024-09-05
PL4504202T3 (pl) 2026-05-04
ES3067080T3 (en) 2026-05-19
TW202345846A (zh) 2023-12-01
CA3255718A1 (en) 2023-10-12
JP2025511352A (ja) 2025-04-15
US20260053802A1 (en) 2026-02-26
MX2024012230A (es) 2024-11-08
EP4504202B1 (en) 2026-02-04
WO2023196329A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2021046430A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
WO2017013160A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
TWI874925B (zh) 癌症治療
US20140178366A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
US20140024030A1 (en) Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status
TW201839399A (zh) 癌症治療
JP2021502415A (ja) 癌の処置のためのアパチニブを用いる併用療法
JP2015529194A (ja) ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
CN119384277A (zh) 使用经取代的嘧啶-4(3h)-酮和索托拉西布的组合疗法
TWI863962B (zh) 癌症治療
US20260053802A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
CN116568326A (zh) 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物
CN116568306A (zh) 用于治疗实体瘤的包含krasg12c抑制剂和egfr抑制剂的方法和组合物
KR20120099219A (ko) 조합물
TW202320790A (zh) 治療癌症之方法
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
HK40118757A (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
WO2014031856A1 (en) Combination therapy using pi3 kinase and braf inhibitors
CN104334192A (zh) 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
HK40111140A (en) Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation
CN118574621A (zh) 取代的嘧啶-4(3h)-酮用于治疗癌症
EA039396B1 (ru) Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118757

Country of ref document: HK